Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Equillium, Inc. is a biotechnology company focused on developing novel immuno-inflammatory therapeutics. Its pipeline includes first-in-class monoclonal antibodies and multi-cytokine inhibitors targeting severe autoimmune and inflammatory diseases such as graft-versus-host disease, celiac disease, and alopecia areata. The company leverages proprietary platforms and strategic partnerships to advance clinical candidates and aims to commercialize therapies that address high unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.